Estrogen neuroprotection and the critical period hypothesis

Erin Scott, Quanguang Zhang, Ruimin Wang, Ratna Vadlamudi, Darrell W Brann

Research output: Contribution to journalReview article

80 Citations (Scopus)

Abstract

17β-Estradiol (estradiol or E2) is implicated as a neuroprotective factor in a variety of neurodegenerative disorders. This review focuses on the mechanisms underlying E2 neuroprotection in cerebral ischemia, as well as emerging evidence from basic science and clinical studies, which suggests that there is a " critical period" for estradiol's beneficial effect in the brain. Potential mechanisms underlying the critical period are discussed, as are the neurological consequences of long-term E2 deprivation (LTED) in animals and in humans after natural menopause or surgical menopause. We also summarize the major clinical trials concerning postmenopausal hormone therapy (HT), comparing their outcomes with respect to cardiovascular and neurological disease and discussing their relevance to the critical period hypothesis. Finally, potential caveats, controversies and future directions for the field are highlighted and discussed throughout the review.

Original languageEnglish (US)
Pages (from-to)85-104
Number of pages20
JournalFrontiers in Neuroendocrinology
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Estradiol
Estrogens
Menopause
Brain Ischemia
Neurodegenerative Diseases
Cardiovascular Diseases
Clinical Trials
Hormones
Brain
Neuroprotection
Therapeutics
Direction compound
Clinical Studies

Keywords

  • Brain
  • Cerebral ischemia
  • Critical period
  • Dementia
  • Estrogen
  • Hormone therapy
  • Menopause
  • Stroke

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems

Cite this

Estrogen neuroprotection and the critical period hypothesis. / Scott, Erin; Zhang, Quanguang; Wang, Ruimin; Vadlamudi, Ratna; Brann, Darrell W.

In: Frontiers in Neuroendocrinology, Vol. 33, No. 1, 01.01.2012, p. 85-104.

Research output: Contribution to journalReview article

Scott, Erin ; Zhang, Quanguang ; Wang, Ruimin ; Vadlamudi, Ratna ; Brann, Darrell W. / Estrogen neuroprotection and the critical period hypothesis. In: Frontiers in Neuroendocrinology. 2012 ; Vol. 33, No. 1. pp. 85-104.
@article{7fe5236523b34b0b8ca6bda0b93a0039,
title = "Estrogen neuroprotection and the critical period hypothesis",
abstract = "17β-Estradiol (estradiol or E2) is implicated as a neuroprotective factor in a variety of neurodegenerative disorders. This review focuses on the mechanisms underlying E2 neuroprotection in cerebral ischemia, as well as emerging evidence from basic science and clinical studies, which suggests that there is a {"} critical period{"} for estradiol's beneficial effect in the brain. Potential mechanisms underlying the critical period are discussed, as are the neurological consequences of long-term E2 deprivation (LTED) in animals and in humans after natural menopause or surgical menopause. We also summarize the major clinical trials concerning postmenopausal hormone therapy (HT), comparing their outcomes with respect to cardiovascular and neurological disease and discussing their relevance to the critical period hypothesis. Finally, potential caveats, controversies and future directions for the field are highlighted and discussed throughout the review.",
keywords = "Brain, Cerebral ischemia, Critical period, Dementia, Estrogen, Hormone therapy, Menopause, Stroke",
author = "Erin Scott and Quanguang Zhang and Ruimin Wang and Ratna Vadlamudi and Brann, {Darrell W}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.yfrne.2011.10.001",
language = "English (US)",
volume = "33",
pages = "85--104",
journal = "Frontiers in Neuroendocrinology",
issn = "0091-3022",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Estrogen neuroprotection and the critical period hypothesis

AU - Scott, Erin

AU - Zhang, Quanguang

AU - Wang, Ruimin

AU - Vadlamudi, Ratna

AU - Brann, Darrell W

PY - 2012/1/1

Y1 - 2012/1/1

N2 - 17β-Estradiol (estradiol or E2) is implicated as a neuroprotective factor in a variety of neurodegenerative disorders. This review focuses on the mechanisms underlying E2 neuroprotection in cerebral ischemia, as well as emerging evidence from basic science and clinical studies, which suggests that there is a " critical period" for estradiol's beneficial effect in the brain. Potential mechanisms underlying the critical period are discussed, as are the neurological consequences of long-term E2 deprivation (LTED) in animals and in humans after natural menopause or surgical menopause. We also summarize the major clinical trials concerning postmenopausal hormone therapy (HT), comparing their outcomes with respect to cardiovascular and neurological disease and discussing their relevance to the critical period hypothesis. Finally, potential caveats, controversies and future directions for the field are highlighted and discussed throughout the review.

AB - 17β-Estradiol (estradiol or E2) is implicated as a neuroprotective factor in a variety of neurodegenerative disorders. This review focuses on the mechanisms underlying E2 neuroprotection in cerebral ischemia, as well as emerging evidence from basic science and clinical studies, which suggests that there is a " critical period" for estradiol's beneficial effect in the brain. Potential mechanisms underlying the critical period are discussed, as are the neurological consequences of long-term E2 deprivation (LTED) in animals and in humans after natural menopause or surgical menopause. We also summarize the major clinical trials concerning postmenopausal hormone therapy (HT), comparing their outcomes with respect to cardiovascular and neurological disease and discussing their relevance to the critical period hypothesis. Finally, potential caveats, controversies and future directions for the field are highlighted and discussed throughout the review.

KW - Brain

KW - Cerebral ischemia

KW - Critical period

KW - Dementia

KW - Estrogen

KW - Hormone therapy

KW - Menopause

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84857371675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857371675&partnerID=8YFLogxK

U2 - 10.1016/j.yfrne.2011.10.001

DO - 10.1016/j.yfrne.2011.10.001

M3 - Review article

C2 - 22079780

AN - SCOPUS:84857371675

VL - 33

SP - 85

EP - 104

JO - Frontiers in Neuroendocrinology

JF - Frontiers in Neuroendocrinology

SN - 0091-3022

IS - 1

ER -